Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.59 |
| ▸ | HTR2A | P28223 | 4/20 | 0.59 |
| ▸ | HTR2B | P41595 | 4/20 | 0.59 |
| ▸ | PNMT | P11086 | 4/20 | 0.57 |
| ▸ | PRCP | P42785 | 1/20 | 0.42 |
| ▸ | CD44 | P16070 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29589119 | 0.87 | PNMT (0.69) | HTR2CHTR2AHTR2BPNMTPRCP | |
| SCHEMBL7636993 | 0.87 | PNMT (0.69) | HTR2CHTR2AHTR2BPNMTPRCP | |
| SCHEMBL29586892 | 0.87 | CD44 (0.58) | HTR2CHTR2AHTR2BPNMTPRCP | |
| SCHEMBL1010480 | 0.87 | CD44 (0.58) | HTR2CHTR2AHTR2BPNMTPRCP | |
| Hydrochloric Acid SCHEMBL17687140 | 0.85 | PNMT (0.67) | HTR2CHTR2AHTR2BPNMTPRCP | |
| Hydrochloric Acid SCHEMBL3070177 | 0.85 | CD44 (0.56) | HTR2CHTR2AHTR2BPNMTPRCP | |
| SCHEMBL30173200 | 0.81 | NOTUM (0.44) | HTR2CHTR2AHTR2BPNMTDRD2 | |
| SCHEMBL2507445 | 0.78 | BCL2L1 (0.52) | PNMT | |
| SCHEMBL9455906 | 0.78 | BCL2L1 (0.47) | PNMTDRD2 | |
| SCHEMBL29625282 | 0.78 | BCL2L1 (0.47) | PNMTDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| CN-116507326-A | Compounds as GLP-1R agonists | 拓臻制药公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-4199919-A1 | COMPOUNDS AS GLP-1R AGONISTS | Terns Pharmaceuticals, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20220089578-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2022-03-24 | — | — | US | disclosed |
| WO-2022040600-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022040600-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| US-7994163-B2 | e.g. 3-tert-Butoxycarbonyl-7-chloro-6-chloromethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; serotonin receptor agonist; antidepressant, anxiolytic agent; obesity, obsessive compulsive disorder | ELI LILLY AND COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| EP-1924560-B1 | 6-SUBSTITUTED- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20080255092-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255092-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists | HTR2C, HTR3C, HTR3A | HTR2C 1/4885HTR2A 10/4885HTR2B 16/4885 |
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | HTR2C 326/4885HTR2A 202/4885HTR2B 333/4885 |
| US-20220089578-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | HTR2C 326/4885HTR2A 202/4885HTR2B 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.